NEW ORLEANS — Idecabtagene vicleucel induced initial complete remission in nearly half of patients with multiple myeloma who had early relapse after front-line therapy, results of a cohort analysis of the phase 2 KarMMa-2 trial showed.
Investigators noted a median duration of response of nearly 2 years among patients who had an initial complete response to idecabtagene vicleucel (Abecma; Bristol Myers Squibb, 2seventy bio) — also known as ide-cel — according to data presented at ASH Annual Meeting and Exposition.
“The expected survival for these patients is quite poor,
